• Our focus
    • Back
    • Our focus
    • Community engagement
    • Understanding brain diseases
      • Migraine awareness
      • Mental health awareness
    • Neurology
      • Alzheimer's Disease
      • Lennox-Gastaut Syndrome
      • Migraine
      • Parkinson's Disease
    • Psychiatry
      • Alcohol Use Disorder
      • Bipolar Disorder
      • Borderline Personality Disorder
      • Depression
      • Generalized Anxiety Disorder
      • Post-Traumatic Stress Disorder
      • Schizophrenia
    • Report a side effect
  • Our science
    • Back
    • Our science
    • Research and development
      • Our value chain
    • Products
    • Pipeline
    • Medical education
      • Lundbeck Institute
    • Clinical trials
      • Clinical trial diversity
      • Study synopses
    • Clinical data sharing
    • Publications
  • Stories
  • Sustainability
    • Back
    • Sustainability
    • ESG Commitments and principles
    • Access to brain health
    • Climate action
    • Donations and grants
    • Health and safety at work
    • Materials use and waste
    • Responsible business conduct
      • Code of Ethics
    • Suppliers and third-parties
    • Transparent interactions
  • About us
    • Back
    • About us
    • Our commitment
      • Inclusion, diversity & equity
      • Our position on Brain Health
      • Our position on Patient Centricity
    • This is Lundbeck
      • At a glance
      • Organization and ownership
      • The Lundbeck Foundation
      • Our history
    • Our leadership
      • Executive Leadership Team
      • Board of Directors
    • Corporate governance
      • Board tasks
      • Remuneration
      • Risk management
  • Code of Ethics
  • Careers
    • Back
    • Careers
    • Life at Lundbeck
      • Our culture and people
      • Building community
      • Employee development
    • Your job
      • Job opportunities
      • Career areas
      • Recruitment process
      • Unsolicited applications
    • Early career programs
      • Students
  • Investors
    • Back
    • Investors
    • Releases
      • Release subscription
    • Financials
    • Reports and presentations
      • Annual Reporting 2025
    • Events
      • Financial calendar and events
      • General meeting
    • Investor Portal
    • The share
      • Share data
      • Shareholders and dividends
      • Analyst coverage
      • New share structure
    • Debt
  • Partnering
    • Back
    • Partnering
    • Partnership initiatives
      • External Research & Innovation
      • Lighthouse Life Science
      • Lundbeck Biotech Incubator
      • HEAD-WINd®
    • Lundbeck CDM
  • Press
  • Contact
  • Other sites (Global)
    • Back
    • Global
      • Back
      • Global site
    • Americas
      • Back
      • Argentina
      • Brazil
      • Canada
      • Chile
      • Colombia
      • Mexico
      • Panama
      • Peru
      • United States
    • Asia
      • Back
      • China
      • Israel
      • Japan
      • Korea
      • Singapore
      • Turkey
    • Europe
      • Back
      • Austria
      • Belgium
      • Bulgaria
      • Czech Republic
      • Denmark
      • Estonia
      • Finland
      • France
      • Germany
      • Greece
      • Ireland
      • Italy
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Slovenia
      • Spain
      • Sweden
      • Switzerland
      • United Kingdom
    • Oceania
      • Back
      • Australia and New Zealand
    • Other Sites
      • Back
      • Drughunters
      • Elaiapharm
      • Lundbeck CDM
      • Lundbeck GBS Krakow
      • Brain Battle
      • Longboard Pharmaceuticals
  1. Home
  • Linkedin
  • Facebook
  • Email
  • Linkedin
  • Facebook
  • Email

Search Results

Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck
Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck
Dr. Johan Luthman udnævnt koncerndirektør for forskning og udvikling hos Lundbeck
Dr. Johan Luthman udnævnt koncerndirektør for forskning og udvikling hos Lundbeck
Lundbeck joins EHDEN
research programme currently in planning.”    Johan Luthman, Executive Vice President, Research & Development, Lundbeck, said, “Joining ...
Program for Drughunters 2019.pdf
Download
pdf, 95 KB
Lundbeck 2020 Q3 Results transcript.pdf
Download
pdf, 170 KB
Invitation RD Day 2023 - Lundbeck.pdf
Download
pdf, 150 KB
Lundbeck_Q1_Transcript.pdf
Download
pdf, 143 KB
ID20251661 - Transcript - Get Visual - Lundbeck 2025-11-12 1300 CET_SONQ.pdf
Download
pdf, 338 KB
caracal.docx
Download
pdf, 215 KB
caracal.docx
Download
pdf, 148 KB
Lundbeck Q3 transcript.pdf
Download
pdf, 223 KB
Press Release RD Event.pdf
Download
pdf, 89 KB
FY2022_transcript.pdf
Download
pdf, 210 KB
1 2 3 4 5 6 7 8 9 10 Next
Johan Luthman. Executive Vice President, R&D
Johan Luthman. Executive Vice President, R&D
Download
jpg, 1 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 22 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 22 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 26 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 18 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 16 MB
Johan Luthman, Executive Vice President, R&D
Johan Luthman, Executive Vice President, R&D
Download
jpg, 17 MB
Johan Luthman.png
Johan Luthman.png
Download
png, 1 MB
Johan-Luthman.jpg
Johan-Luthman.jpg
Download
jpg, 1 MB
Johan_Luthman.jpg
Johan_Luthman.jpg
Download
jpg, 148 KB
1 2 Next

H. Lundbeck A/S

Ottiliavej 9
2500 Valby
Denmark

Headquarters

  • +45 3630 1311
  • info@lundbeck.com

Links

  • Report a side effect
  • Compliance hotline
  • Terms of use
  • Contact us
  • Social media principles
  • Cookie settings

Connect with us

Privacy policy

Copyright© 2026 H. Lundbeck A/S